Blueprint Medicines Reports Long-Term Efficacy Data for AYVAKIT in Systemic Mastocytosis at ASH 2025
核心洞察
Blueprint Medicines presented multi-year clinical data at ASH 2025 showing AYVAKIT (avapritinib) maintains sustained efficacy across both indolent and advanced systemic mastocytosis (搜索) with durable symptom control.
In advanced systemic mastocytosis (搜索) first-line treatment, AYVAKIT achieved an 87% overall response rate with median overall survival not yet reached after four years of follow-up.
Long-term safety data spanning over three years demonstrated a favorable tolerability profile with only 3% discontinuation rate due to treatment-related adverse events in indolent systemic mastocytosis (搜索) patients.
Blueprint Medicines, a Sanofi company, presented compelling long-term clinical data for AYVAKIT (avapritinib) at the 67th American Society of Hematology Annual Meeting, demonstrating sustained efficacy and safety across the spectrum of systemic mastocytosis (搜索) after multiple years of treatment. The comprehensive dataset reinforces AYVAKIT's position as the global standard of care for both indolent and advanced forms of this rare KIT D816V (搜索)-driven disease.
Sustained Survival Benefits in Advanced Disease
In the PATHFINDER trial analysis of patients with advanced systemic mastocytosis (搜索) receiving first-line AYVAKIT, the results showed remarkable durability. Among 38 treatment-naïve patients, the overall response rate reached 87%, with 43% achieving complete remissions with full or partial hematologic recovery. After a median follow-up of more than four years, the median overall survival was not reached, with an estimated 48-month overall survival rate of 79% and progression-free survival rate of 67%.
"AYVAKIT has become the global standard of care across the spectrum of the disease, with robust datasets highlighting sustained quality-of-life benefits in ISM, favorable survival outcomes in advanced SM and a well-characterized safety profile supporting chronic treatment," said Mik Rinne, M.D., Ph.D., Head of Development at Blueprint Medicines.
The survival data represents a significant improvement over historical outcomes. In a prior clinical trial of midostaurin, the median overall survival was 28.7 months for patients with advanced systemic mastocytosis (搜索). A separate analysis focusing on intermediate- and high-risk patients showed AYVAKIT was associated with improved overall survival relative to midostaurin with a hazard ratio of 0.08 (p<0.001).
Durable Symptom Control in Indolent Disease
The PIONEER trial data in indolent systemic mastocytosis (搜索) demonstrated sustained clinical benefits after a median follow-up of more than three years. Among 226 patients, AYVAKIT showed sustained improvements in overall symptoms across all domains including skin, gastrointestinal, and neurocognitive symptoms as measured by the ISM Symptom Assessment Form, along with quality of life improvements per the Mastocytosis Quality of Life Questionnaire.
The long-term safety profile proved particularly favorable, with only a 3% discontinuation rate due to treatment-related adverse events across the overall trial population. Edema was the most common treatment-related adverse event, with the majority of these events being mild (Grade 1).
Disease-Modifying Effects on Bone Health
Across both disease subtypes, AYVAKIT demonstrated significant improvements in bone health, suggesting disease-modifying effects beyond symptom management. In indolent systemic mastocytosis (搜索) patients receiving dual-energy X-ray absorptiometry scans (n=79), AYVAKIT led to durable benefits in bone health independent of concomitant use of other treatments known to improve bone density.
Similarly, in advanced systemic mastocytosis (搜索) patients receiving DXA scans across lines of therapy (n=56), 21% had low bone density at baseline. In this population, AYVAKIT significantly increased bone density versus baseline levels (p<0.05).
Safety Profile Supports Chronic Treatment
The comprehensive safety analysis across both trials confirmed AYVAKIT's tolerability for long-term use. In advanced systemic mastocytosis (搜索) patients across lines of therapy (N=107), AYVAKIT maintained a favorable benefit-risk profile consistent with previously reported data. Common treatment-related adverse events included edema (periorbital and peripheral), thrombocytopenia, and anemia.
The drug carries important safety considerations, including monitoring for intracranial hemorrhage, particularly in advanced systemic mastocytosis (搜索) patients with platelet counts below 50,000/μL. Cognitive effects occurred in 33% of patients overall, though these were generally manageable with dose modifications.
Clinical Impact and Market Position
The long-term data presentations included one oral presentation and seven poster presentations, covering various aspects of AYVAKIT's clinical profile from clonal dynamics to artificial intelligence-based assessment of skin lesions. The comprehensive evidence base supports AYVAKIT's role as the first and only FDA-approved medicine to treat the root cause of systemic mastocytosis (搜索).
AYVAKIT received FDA approval for advanced systemic mastocytosis (搜索) in June 2021 and for indolent systemic mastocytosis (搜索) in May 2023. The drug is now approved globally in more than 35 countries for one or more indications, with Blueprint Medicines noting that the presentations "reinforce the urgency to treat the root cause of SM to mitigate its significant health complications."